Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hADME and Absolute Bioavailability of BI 1815368 in Healthy Males
NCT07693218Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 1815368, sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [14C]-radioactivity excreted in urine up to 24 days, Fraction of [14C]-radioactivity excreted in faeces up to 24 days and 2 more. Started Jul 2026; status: completed.
02
Drugs
BI 1815368
Beyond the preview
Go deeper on NCT07693218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07693218.